Last reviewed · How we verify
Clinical Study of Recombinant CD19xCD3 Double Antibody (A-319) in the Treatment of Active/Refractory Systemic Lupus Erythematosus
The purpose of the study is to explore the safety and efficacy of recombinant CD19xCD3 double antibody (A-319) in active/refractory systemic lupus erythematosus (SLE).
Details
| Lead sponsor | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology |
|---|---|
| Phase | Phase 1 |
| Status | RECRUITING |
| Enrolment | 25 |
| Start date | 2024-07-20 |
| Completion | 2026-12 |
Conditions
- Systemic Lupus Erythematosus
Interventions
- A-319
Primary outcomes
- Safety and tolerability — Within 1 year since A-319 infusion
Safety and tolerability will be assessed by incidence and severity of adverse events (AEs) and serious AEs (SAEs)
Countries
China